2. Academic Validation
  3. The research progression of direct NLRP3 inhibitors to treat inflammatory disorders

The research progression of direct NLRP3 inhibitors to treat inflammatory disorders

  • Cell Immunol. 2024 Mar-Apr:397-398:104810. doi: 10.1016/j.cellimm.2024.104810.
Xiu Chen 1,  Pingping Zhang 1,  Yu Zhang 1,  Mengzhu Wei 1,  Tian Tian 1,  Dacheng Zhu 1,  Yanling Guan 1,  Wei Wei 2,  Yang Ma 3
Affiliations

Affiliations

  • 1 Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammasome and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammasome and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei 230032, China.
  • 2 Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammasome and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammasome and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei 230032, China. Electronic address: wwei@ahmu.edu.cn.
  • 3 Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammasome and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammasome and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei 230032, China. Electronic address: mayang_ahmu@126.com.
PMID: 38324950 DOI: 10.1016/j.cellimm.2024.104810
Abstract

The NLRP3 inflammasome represents a cytoplasmic multiprotein complex with the capability to recognize a wide range of pathogen-derived, environmental, and endogenous stress-related factors. Dysregulated activation of the NLRP3 inflammasome has been implicated in the development of various inflammasome-associated disorders, highlighting its significance as a pivotal target for the treatment of inflammatory diseases. Nonetheless, despite its clinical importance, there is currently a lack of specific drugs available for directly targeting the NLRP3 inflammasome. Several strategies have been explored to target different facets of the NLRP3 inflammasome, with interventions aimed at directly inhibiting NLRP3 demonstrating the most promising efficacy and safety profiles. In this review, we provide a summary of direct inhibitors targeting NLRP3, elucidating their inhibitory mechanisms, clinical trial phases, and potential applications. Through this discussion, we aim to shed LIGHT on the implications of NLRP3 inhibition for the treatment of inflammatory diseases.

Keywords

Direct inhibitors; Inflammatory diseases; NLRP3 inflammasome.

Figures
Products